Overview

• Bausch Health Q2 2025 revenue rises 5% yr/yr to $2.53 bln

• Adjusted EBITDA for Q2 grows 6% to $842 mln

• Co plans upcoming $900 mln debt repayment afetr quarter-end

• Announced to acquire DURECT Corporation in July

Outlook

• Company reaffirms full-year 2025 revenue and adjusted EBITDA guidance

• Bausch Health increases full-year revenue guidance to $10.0-$10.25 bln

• Company sees full-year adjusted EBITDA between $3.485 bln and $3.635 bln

• Company acknowledges uncertainty due to tariffs and economic conditions

Result Drivers

• SALIX SEGMENT - Revenue increased 12% driven by Xifaxan's 10% growth

• SOLTA MEDICAL SEGMENT - Revenue rose 25%, led by growth in South Korea

• DIVERSIFIED SEGMENT - Revenue declined 13% due to divestitures and discontinuations

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 5 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for Bausch Health Companies Inc is $7.00, about 2.6% above its July 29 closing price of $6.82

• The stock recently traded at 2 times the next 12-month earnings vs. a P/E of 1 three months ago

Press Release: ID:nACSMMjhpa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)